Cost and effectiveness of hepatitis C virus cryoglobulinemia vasculitis (HCV-CryoVas) treatment in the era of direct acting antivirals (DAA) in a tertiary French center

被引：0
|
作者：
Cacoub, Patrice P. [1 ,2 ]
Vautier, Mathieu [1 ,2 ]
Desbois, Anne Claire [1 ,2 ]
Doz, Marianne [3 ]
Lafuma, Antoine [3 ]
机构：
[1] Grp Hosp Pitie Salpetriere, AP HP, Dept Internal Med & Clin Immunol, Paris, France
[2] Univ Paris 06, Sorbonne Univ, UMR 7211, Inflammat Immunopathol Biotherapy Dept DHU I2B, Paris, France
[3] CEMKA, Paris, France
来源：
HEPATOLOGY | 2016年 / 64卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
817
引用
收藏
页码：402A / 402A
页数：1
相关论文
共 50 条
  • [21] Cost-effectiveness of direct-acting antivirals for chronic hepatitis C
    Gaby Sroczynski
    Uwe Siebert
    Nature Reviews Gastroenterology & Hepatology, 2013, 10 : 572 - 574
  • [22] Treatment of Hepatitis C Virus Infection in Patients With Cancer in the Era of Direct Acting Antivirals: An Indonesian National Cancer Center Experience
    不详
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2020, 115 : S1707 - S1707
  • [23] Early View of the Effectiveness of New Direct-Acting Antiviral (DAA) Regimens in Patients with Hepatitis C Virus (HCV)
    Walker, David R.
    Pedrosa, Marcos C.
    Manthena, Shivaji R.
    Patel, Nikil
    Marx, Steven E.
    ADVANCES IN THERAPY, 2015, 32 (11) : 1117 - 1127
  • [24] Early View of the Effectiveness of New Direct-Acting Antiviral (DAA) Regimens in Patients with Hepatitis C Virus (HCV)
    David R. Walker
    Marcos C. Pedrosa
    Shivaji R. Manthena
    Nikil Patel
    Steven E. Marx
    Advances in Therapy, 2015, 32 : 1117 - 1127
  • [25] Hepatitis C virus infection treatment: An era of game changer direct acting antivirals and novel treatment strategies
    Shahid, Imran
    ALMalki, Waleed Hassan
    Hafeez, Muhammad Hassan
    Hassan, Sajida
    CRITICAL REVIEWS IN MICROBIOLOGY, 2016, 42 (04) : 535 - 547
  • [26] The effectiveness and safety of direct-acting antivirals for hepatitis C virus treatment: A single-center experience in Saudi Arabia
    Alarfaj, Sumaiah J.
    Alzahrani, Abdullah
    Alotaibi, Anfal
    Almutairi, Malak
    Hakami, Mashael
    Alhomaid, Njood
    Alharthi, Noori
    Korayem, Ghazwa B.
    Alghamdi, Abdullah
    SAUDI PHARMACEUTICAL JOURNAL, 2022, 30 (10) : 1448 - 1453
  • [27] Hepatitis C virus re-treatment in the era of direct-acting antivirals: projections in the USA
    Chhatwal, J.
    Chen, Q.
    Ayer, T.
    Bethea, E. D.
    Kanwal, F.
    Kowdley, K. V.
    Wang, X.
    Roberts, M. S.
    Gordon, S. C.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2018, 47 (07) : 1023 - 1031
  • [28] New era in the treatment of chronic hepatitis C - novel direct acting antivirals
    Horvath Gabor
    Halasz Tuende
    Makara Mihaly
    Hunyady Bela
    ORVOSI HETILAP, 2015, 156 (21) : 841 - 848
  • [29] Future of liver disease in the era of direct acting antivirals for the treatment of hepatitis C
    Francesca Romana Ponziani
    Francesca Mangiola
    Cecilia Binda
    Maria Assunta Zocco
    Massimo Siciliano
    Antonio Grieco
    Gian Lodovico Rapaccini
    Maurizio Pompili
    Antonio Gasbarrini
    World Journal of Hepatology, 2017, (07) : 352 - 367
  • [30] Treatment of hepatitis C infections in the era of direct-acting antivirals (DAAs)
    Peiffer, Kai-Henrik
    Zeuzem, Stefan
    BUNDESGESUNDHEITSBLATT-GESUNDHEITSFORSCHUNG-GESUNDHEITSSCHUTZ, 2022, 65 (02) : 246 - 253
12345